Cullinan Therapeutics Inc’s recently made public that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $4.19 million on Oct 09 ’25. In the deal valued at $6.70 per share,626,043 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 8,271,786 shares worth roughly $61.21 million.
Then, Lynx1 Capital Management LP bought 556,300 shares, generating $3,593,698 in total proceeds. Upon buying the shares at $6.46, the 10% Owner now owns 7,645,743 shares.
Before that, Lynx1 Capital Management LP bought 277,298 shares. Cullinan Therapeutics Inc shares valued at $2,041,385 were divested by the 10% Owner at a price of $7.36 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 8,549,084 shares, worth roughly $63.26 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Friday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock jump 4.96% to $7.4. Over the last five days, the stock has gained 25.42%. Cullinan Therapeutics Inc shares have fallen nearly -54.07% since the year began. Nevertheless, the stocks have fallen -39.24% over the past one year.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-09-30, dropping by -0.14 million shares to a total of 6.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 6.24 million shares. There was a decline of -2.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
